5th Update on Fabry Nephropathy: Biomarkers, Progression and Treatment Opportunities. April 25-27, 2017, Mexico City, Mexico: Abstracts.

08:00 EDT 22nd April 2017 | BioPortfolio

Summary of "5th Update on Fabry Nephropathy: Biomarkers, Progression and Treatment Opportunities. April 25-27, 2017, Mexico City, Mexico: Abstracts."

No Summary Available


Journal Details

This article was published in the following journal.

Name: Nephron
ISSN: 2235-3186
Pages: 163-182


DeepDyve research library

PubMed Articles [24346 Associated PubMed Articles listed on BioPortfolio]

Hemizygous Fabry disease associated with membranous nephropathy: A rare case report

Fabry disease may coexist with various glomerular diseases, including IgA nephropathy, focal segmental glomerulosclerosis, etc. In this study, we report a rare case of Fabry disease associated with me...

Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy.

The addition of immunosuppression to supportive care reduces proteinuria in a subset of patients with IgA nephropathy (IgAN) but is associated with an increased rate of adverse events. The present wor...

Potential Value of Urinary Exosome-Derived let-7c-5p in the Diagnosis and Progression of Type II Diabetic Nephropathy.

Diabetic nephropathy (DN) is a leading cause of death worldwide. Reliable biomarkers are demanded for the non-invasive diagnosis of DN. This study aims to investigate whether miRNA in urinary exosomes...

Mapping Txnip: Key connexions in progression of diabetic nephropathy.

Studies demonstrates the major involvement of inflammatory and apoptotic pathway in the pathophysiology of diabetic nephropathy. The cross talk between inflammatory and apoptotic pathway suggests Txni...

Proposed Stages of Myocardial Phenotype Development in Fabry Disease.

The authors sought to explore the Fabry myocardium in relation to storage, age, sex, structure, function, electrocardiogram changes, blood biomarkers, and inflammation/fibrosis.

Clinical Trials [6337 Associated Clinical Trials listed on BioPortfolio]

Biomarkers and Progression of IgA Nephropathy

This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chi...

Fabry Outcome Survey (FOS)

The purpose of this study is to collect data that will increase understanding of Fabry disease history and progression, in treated and untreated patients with Fabry disease. The data from ...

Biomarkers for the Progression of IgA Nephropathy

IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and an important cause of end stage renal disease. IgAN has an incidence of 8-25 new cases/year/per millio...

Fabry Disease Registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of trea...

Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy

In patients with Fabry disease, this research study explores the presence of podocytes in their urine as a potential non-invasive biomarker for baseline kidney disease; and explores change...

Medical and Biotech [MESH] Definitions

A factor associated with the well-being of living organisms that is used as a measure of environmental change and or influence. For example, aldehyde dehydrogenase expression in earthworm tissue is used as an indication of heavy metal pollution in soils. Distinguish from BIOMARKERS.

Differential treatment or unequal access to opportunities, based on group membership such as origin or ethnicity.

Differential treatment or unequal access to opportunities or services based on perceived homosexual preference or orientation.

Biased behaviors or attitudes, differential treatment, unequal access to social participation or opportunities based on age.

A method of providing future reproductive opportunities before a medical treatment with known risk of loss of fertility. Typically reproductive organs or tissues (e.g., sperm, egg, embryos and ovarian or testicular tissues) are cryopreserved for future use before the medical treatment (e.g., chemotherapy, radiation) begins.

Quick Search


DeepDyve research library

Searches Linking to this Article